Molecular Insights into the Impact of Bone Marrow Stroma, CB-6644 Inhibition of the RUVBL1/2 Complex, and CEBPβ on Regulating Drug Sensitivity in Multiple Myeloma

Multiple myeloma (MM), is a hematological cancer originating in plasma cells. Currently multiple myeloma represents a significant clinical challenge due its incurable nature mainly due to inevitable drug resistance. MM is characterized by abnormal plasma cell proliferation within the bone marrow and production of abnormal immunoglobulin resulting in a plethora of physiological abnormalities. Although a rare malignancy, MM accounts for 1% of all cancers and currently has five-year survival rate of around 50%. Utilizing a combination of laboratory experiments and bioinformatics techniques, this dissertation examines multiple layers of MM physiology in the context of regulating drug resistance or sensitivity. First, we examine the influence of bone marrow stromal cells on MM transcriptome related to stromal cells induced drug resistance. Secondly, we assess novel anti-MM therapeutics candidate like CB-6644, and lastly investigates the transcription factor CEBPβ's role in modulating dexamethasone sensitivity.